Streetbeat News

Earnings

LI

Financial analysts have observed a bearish sentiment among options traders for Li Auto (NASDAQ:LI), with 80% of the unusual trades being puts. The trades suggest that big players anticipate Li Auto's stock to stay within $35.0 to $40.0. Li Auto, a Chinese NEV manufacturer, has seen its stock price increase by 3.03% to $38.08, with a high trading volume and potential overbought RSI readings. The company's next earnings release is expected in 105 days.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 7:15 pm

RILY

B. Riley Financial, Inc. (NASDAQ:RILY) stock has declined over 37% in the last five days due to continued downward momentum. The company became the largest minority shareholder in Franchise Group (FRG) after leading its equity financing in August. FRG's credit rating was downgraded by S&P, and its CEO is under investigation in a federal fraud case. B. Riley reported Q3 losses of $2.53 per share, a significant decrease from the previous year, despite a 48% increase in quarterly sales. The stock's trading volume surged, with over 3.67 million shares traded compared to the 100-day average of 375 thousand shares.

Portfolio Pulse from Erica Kollmann

November 13, 2023 | 7:14 pm

AMD

ARM

INTC

Citi analyst Christopher Danely has reiterated a Buy rating on Advanced Micro Devices, Inc (AMD), noting that the company has gained significant market share in MPU units according to Mercury Research's estimates for 3Q23. AMD's market share increased to 17.7%, while Intel Corp (INTC) and Arm Holdings Plc (ARM) saw declines in their shares. Danely projects higher EPS for AMD in CY23 and CY24 compared to consensus estimates. AMD's stock traded lower by 1.62% at the last check.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 7:04 pm

LLY

NVO

PFE

Pfizer Inc (PFE) is targeting the obesity pill market with its experimental drug, danuglipron, aiming for a $10 billion segment. Pfizer discontinued another candidate, lotiglipron, due to unsatisfactory Phase 1 results. Competitors Eli Lilly (LLY) and Novo Nordisk (NVO) have set high standards in the weight loss drug industry. Pfizer's upcoming phase two trial data for danuglipron is eagerly awaited by investors, with results expected by year-end for the twice-daily pill and early next year for a once-daily version. Despite a 40% share price drop, Pfizer's CEO sees a $90 billion market potential for GLP-1s. Analysts highlight the need for Pfizer's pill to achieve a 14%-15% weight loss to compete with Eli Lilly's product. PFE shares were down 1.44% at $29.06 on the last check Monday.

Portfolio Pulse from Vandana Singh

November 13, 2023 | 7:04 pm

CTAS

Truist Securities analyst Jasper Bibb initiated coverage on Cintas Corp (NASDAQ:CTAS) with a Buy rating and a price target of $625. Bibb expects Cintas to achieve high incremental margins and a 10%+ increase in FY26 consensus EPS over the next 24 months due to moderating wage inflation, favorable material pricing trends, and Smart Truck initiative efficiencies. The First Aid and Fire segments are projected to deliver a ~10% organic CAGR over five years, improving segment margins to over 20%. Share repurchases are anticipated to increase in FY24/FY25 with net leverage at 1.0x. Bibb's EPS estimates for FY25 and FY24 are $16.92 and $14.22, respectively, both above consensus.

Portfolio Pulse from Lekha Gupta

November 13, 2023 | 6:58 pm

WMT

Analysts from Stephens & Co and Stifel have provided updates on Walmart Inc (NYSE:WMT), with Stephens & Co raising their price target from $185 to $190 and maintaining an Overweight rating, while Stifel raised their price target from $169 to $171 with a Hold rating. Walmart is recognized for its success across all income levels and is expected to continue growing due to its omnichannel experience and low-price positioning. The company is also anticipated to improve margins following significant investments. Both analysts have increased their EPS estimates for the upcoming quarters and fiscal years.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 6:54 pm

AAPL

Citi analyst Atif Malik observed that Apple Inc's Taiwanese suppliers, including Hon Hai, Pegatron, and Wistron, reported a 10% month-on-month sales growth for October, outperforming the 3-year average seasonality. Despite concerns about iPhone sell-through in China with the Huawei Mate 60 launch, U.S. sales remain strong. Malik has not observed supply chain build cuts and maintains his estimate of 81 million iPhone 15 units for CY23. Apple's stock traded down by 0.76% at $184.98.

Portfolio Pulse from Anusuya Lahiri

November 13, 2023 | 6:51 pm

ABM

Truist Securities analyst Jasper Bibb initiated coverage on ABM Industries Inc with a Hold rating and a price target of $43. Concerns about ABM's office exposure, which accounts for approximately 40% of revenue, may hinder growth in the B&I segment. The analyst is cautious about the office market's impact on FY25 estimates and sees a protracted downturn as a risk. Despite this, ABM's adjusted EBITDA margins have improved, and the company trades at a 12% FCF yield based on CY24E adjusted FCF per share estimates. ABM's Q3 FY23 revenue exceeded consensus, but adjusted EPS fell short.

Portfolio Pulse from Lekha Gupta

November 13, 2023 | 6:46 pm

HSIC

Henry Schein's stock is trading higher following the release of their third-quarter results and the issuance of guidance for the full year 2023.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 6:19 pm

SPCB

SuperCom (NASDAQ:SPCB) is expected to release its quarterly earnings report on Tuesday, 2023-11-14, with analysts estimating an EPS of $0.00. Investors are looking for an earnings beat and positive guidance for future growth. Historically, SuperCom's stock price has been volatile post-earnings, with a 14.7% drop after last quarter's beat. Over the past year, SPCB shares have declined by 84.15%, indicating potential concern among long-term shareholders ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:02 pm